Obsidian Therapeutics, Inc.
OBX
$17.77
-$1.15-6.08%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.55M | 5.48M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.28M | 26.60M | |||
| Operating Income | -20.28M | -26.60M | |||
| Income Before Tax | -19.63M | -24.99M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.63M | -24.99M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.63M | -24.99M | |||
| EBIT | -20.28M | -26.60M | |||
| EBITDA | -19.94M | -26.23M | |||
| EPS Basic | -186.21 | -- | |||
| Normalized Basic EPS | -116.38 | -- | |||
| EPS Diluted | -186.21 | -- | |||
| Normalized Diluted EPS | -116.38 | -- | |||
| Average Basic Shares Outstanding | 105.40K | -- | |||
| Average Diluted Shares Outstanding | 105.40K | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||